Eunice Yuen
Director, PK/PD & Pharmacometrics Eli Lilly & Co.
Dr. Eunice Yuen is Director, PK/PD/Pharmacometrics at Eli Lilly & Company, specializing in clinical pharmacology and use of pharmacometrics in oncology drug development. With over 20 years’ experience, she has led PK/PD efforts on projects spanning preclinical to submission phases and across several therapeutic areas. She is published widely and holds a PhD from Manchester University.
Seminars
Navigating dose escalation and selection is a crucial stage in early development to set up ADC performance for success under Project Optimus guidelines
Don’t miss this Eli Lilly-led workshop to delve into all things ADC clinical pharmacology across quantitative systems pharmacology and clinical utility index approaches to optimise your ADC dose selection
Workshop highlights include:
- Utilising quantitative systems pharmacology to investigate ADC preclinical PK/PD characterisation
- Leveraging clinical utility index approach to assess the benefit-risk profiles of ADCs
- Understanding ADC-specific clinical pharmacology considerations and assessing lessons learnt from ADC dose capping
